Elite Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Elite Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$166K	Buy	+3,600	New	+$188K	0.27%	42
2016 Q1	–	Sell	-3,600	Closed	-$236K	–	43
2015 Q4	$236K	Hold	3,600	–	–	0.35%	37
2015 Q3	$203K	Sell	3,600 -50	-1%	-$3.24K	0.32%	56
2015 Q2	$215K	Hold	3,650	–	–	0.22%	55
2015 Q1	$227K	Sell	3,650 -700	-16%	-$40.7K	0.2%	56
2014 Q4	$250K	Hold	4,350	–	–	0.24%	53
2014 Q3	$234K	Buy	4,350 +4,300	+8,600%	+$228K	0.21%	66
2014 Q2	$3K	Hold	50	–	–	﹤0.01%	366
2014 Q1	$3K	Hold	50	–	–	﹤0.01%	295
2013 Q4	$2K	Buy	+50	New	+$1.97K	﹤0.01%	703

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Elite Wealth Management's TEVA Position: Q3 2016 in Review

Elite Wealth Management opened a new position in Teva Pharmaceuticals (TEVA) in Q3 2016: 3,600 shares worth $166K. The stake represents 0.27% of the portfolio and ranks #42 among its holdings. This is a return to the name: Elite Wealth Management previously reported a position in TEVA as recently as Q4 2015.

Elite Wealth Management first reported a position in TEVA in Q4 2013 and has held it in 10 quarters since. The position peaked at $250K in Q4 2014. 796 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Elite Wealth Management held 3,600 shares of Teva Pharmaceuticals worth $166K as of Q3 2016.
Teva Pharmaceuticals was a new Elite Wealth Management position in Q3 2016.
Teva Pharmaceuticals made up 0.27% of Elite Wealth Management's portfolio in Q3 2016, its #42 holding.
Elite Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 10 quarters since.
Elite Wealth Management's Teva Pharmaceuticals position peaked at $250K in Q4 2014.
796 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Elite Wealth Management's 13F filing for Q3 2016, filed 23 Nov 2016.